{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362825893598413184.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1182/blood-2008-07-170449"}},{"identifier":{"@type":"URI","@value":"http://ashpublications.org/blood/article-pdf/113/13/2895/1305380/zh801309002895.pdf"}}],"dc:title":[{"@value":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Abstract</jats:title><jats:p>Therapeutic decision-making in primary myelofibrosis (PMF) is becoming more challenging because of the increasing use of allogeneic stem cell transplantation and new investigational drugs. To enhance this process by developing a highly discriminative prognostic system, 1054 patients consecutively diagnosed with PMF at 7 centers were studied. Overall median survival was 69 months (95% confidence interval [CI]: 61-76). Multivariate analysis of parameters obtained at disease diagnosis identified age greater than 65 years, presence of constitutional symptoms, hemoglobin level less than 10 g/dL, leukocyte count greater than 25 × 109/L, and circulating blast cells 1% or greater as predictors of shortened survival. Based on the presence of 0 (low risk), 1 (intermediate risk-1), 2 (intermediate risk-2) or greater than or equal to 3 (high risk) of these variables, 4 risk groups with no overlapping in their survival curves were delineated; respective median survivals were 135, 95, 48, and 27 months (P < .001). Compared with prior prognostic models, the new risk stratification system displayed higher predictive accuracy, replicability, and discriminating power. In 409 patients with assessable metaphases, cytogenetic abnormalities were associated with shorter survival, but their independent contribution to prognosis was restricted to patients in the intermediate-risk groups. JAK2V617F did not cluster with a specific risk group or affect survival.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382825893598413188","@type":"Researcher","foaf:name":[{"@value":"Francisco Cervantes"}],"jpcoar:affiliationName":[{"@value":"Hematology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893598413313","@type":"Researcher","foaf:name":[{"@value":"Brigitte Dupriez"}],"jpcoar:affiliationName":[{"@value":"Centre Hospitalier, Lens and Lille, France;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893598413316","@type":"Researcher","foaf:name":[{"@value":"Arturo Pereira"}],"jpcoar:affiliationName":[{"@value":"Hematology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893598413185","@type":"Researcher","foaf:name":[{"@value":"Francesco Passamonti"}],"jpcoar:affiliationName":[{"@value":"Hematology Division, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S Matteo, University of Pavia, Pavia, Italy;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893598413186","@type":"Researcher","foaf:name":[{"@value":"John T. Reilly"}],"jpcoar:affiliationName":[{"@value":"Royal Hallamshire Hospital, Sheffield, United Kingdom;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893598413315","@type":"Researcher","foaf:name":[{"@value":"Enrica Morra"}],"jpcoar:affiliationName":[{"@value":"Universita Milano-Niguarda, Milan, Italy;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893598413312","@type":"Researcher","foaf:name":[{"@value":"Alessandro M. Vannucchi"}],"jpcoar:affiliationName":[{"@value":"University of Florence, Florence, Italy;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893598413317","@type":"Researcher","foaf:name":[{"@value":"Ruben A. Mesa"}],"jpcoar:affiliationName":[{"@value":"Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN; and"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893598413318","@type":"Researcher","foaf:name":[{"@value":"Jean-Loup Demory"}],"jpcoar:affiliationName":[{"@value":"Centre Hospitalier, Lens and Lille, France;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893598413184","@type":"Researcher","foaf:name":[{"@value":"Giovanni Barosi"}],"jpcoar:affiliationName":[{"@value":"Unit of Clinical Epidemiology, Center for the Study of Myelofibrosis, Fondazione IRCCS Policlinico S Matteo, Pavia, Italy"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893598413314","@type":"Researcher","foaf:name":[{"@value":"Elisa Rumi"}],"jpcoar:affiliationName":[{"@value":"Hematology Division, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S Matteo, University of Pavia, Pavia, Italy;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893598413187","@type":"Researcher","foaf:name":[{"@value":"Ayalew Tefferi"}],"jpcoar:affiliationName":[{"@value":"Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN; and"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00064971"},{"@type":"EISSN","@value":"15280020"}],"prism:publicationName":[{"@value":"Blood"}],"dc:publisher":[{"@value":"American Society of Hematology"}],"prism:publicationDate":"2009-03-26","prism:volume":"113","prism:number":"13","prism:startingPage":"2895","prism:endingPage":"2901"},"reviewed":"false","url":[{"@id":"http://ashpublications.org/blood/article-pdf/113/13/2895/1305380/zh801309002895.pdf"}],"createdAt":"2008-11-07","modifiedAt":"2025-02-02","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004231200523776","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004231520681728","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004239704829440","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Recent advances in the diagnosis and management of primary myelofibrosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285706497367808","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285706497614208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285708374084736","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285709104275072","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294643813452928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"CAMK2G is identified as a novel therapeutic target for myelofibrosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360572092647505280","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848656450433536","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848657073194880","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Generation of induced pluripotent stem cells derived from primary and secondary myelofibrosis patient samples"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848664140999168","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865815685167360","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204873799808","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Frequency of Calreticulin (CALR) Mutation and Its Clinical Prognostic Significance in Essential Thrombocythemia and Primary Myelofibrosis: A Meta-analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204875041664","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206448206976","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"6. Management of Myelofibrosis"},{"@language":"ja","@value":"6．骨髄線維症"},{"@value":"骨髄線維症"},{"@language":"ja-Kana","@value":"コツズイ センイショウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206449610624","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"1）骨髄増殖性腫瘍の治療"},{"@language":"en","@value":"1. Therapeutic Strategy for Myeloproliferative Neoplasms"}]},{"@id":"https://cir.nii.ac.jp/crid/1390002184880439936","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"7. Diagnosis and Treatment of Chronic Myeloid Leukemia and Myeloproliferative Neoplasms"},{"@language":"ja","@value":"7．慢性骨髄性白血病と骨髄増殖性腫瘍の診断と治療"},{"@value":"慢性骨髄性白血病と骨髄増殖性腫瘍の診断と治療"},{"@language":"ja-Kana","@value":"マンセイ コツズイセイ ハッケツビョウ ト コツズイ ゾウショクセイ シュヨウ ノ シンダン ト チリョウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679219437312","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Splenic Irradiation as a Component of a Reduced-Intensity Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Myelofibrosis with Massive Splenomegaly"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679251517184","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"JAK阻害薬ルキソリチニブ（ジャカビ錠<sup>®</sup>）の薬理学的特長および臨床成績"},{"@language":"en","@value":"Pharmacological characteristic and clinical data of Ruxolitinib (JAKAVI tablet)"},{"@value":"新薬紹介総説 JAK阻害薬ルキソリチニブ(ジャカビ錠)の薬理学的特長および臨床成績"},{"@language":"ja-Kana","@value":"シンヤク ショウカイ ソウセツ JAK ソガイヤク ルキソリチニブ(ジャカビジョウ)ノ ヤクリガクテキ トクチョウ オヨビ リンショウ セイセキ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680397356544","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Allogeneic hematopoietic stem cell transplantation for primary and secondary myelofibrosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1390285300174230912","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A Case of Myelofibrosis Complicated Acquired Von Willebrand Syndrome"},{"@language":"ja","@value":"後天性von Willebrand症候群を合併した骨髄線維症の1例"},{"@value":"今月の症例 後天性von Willebrand症候群を合併した骨髄線維症の1例"},{"@language":"ja-Kana","@value":"コンゲツ ノ ショウレイ コウテンセイ von Willebrand ショウコウグン オ ガッペイ シタ コツズイ センイショウ ノ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390292737788448768","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hematopoietic stem cell transplantation for myeloproliferative neoplasms"},{"@language":"ja","@value":"骨髄増殖性腫瘍に対する造血細胞幹細胞移植"}]},{"@id":"https://cir.nii.ac.jp/crid/1390857226428860800","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Splenic Infarction in Patients with Philadelphia-negative Myeloproliferative Neoplasms"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1182/blood-2008-07-170449"},{"@type":"CROSSREF","@value":"10.1007/s00277-017-3082-y_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"},{"@type":"CROSSREF","@value":"10.1007/s12185-016-2130-z_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"},{"@type":"CROSSREF","@value":"10.3904/kjim.2018.033_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"},{"@type":"CROSSREF","@value":"10.1016/j.exphem.2014.03.010_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.9124-21_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"},{"@type":"CROSSREF","@value":"10.1007/s12185-016-2102-3_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"},{"@type":"CROSSREF","@value":"10.1007/s12185-017-2332-z_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"},{"@type":"CROSSREF","@value":"10.1038/bmt.2013.180_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"},{"@type":"CROSSREF","@value":"10.1080/03007995.2017.1415874_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"},{"@type":"CROSSREF","@value":"10.2169/naika.101.1969_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"},{"@type":"CROSSREF","@value":"10.7889/tct-22-006_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.8491-16_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"},{"@type":"CROSSREF","@value":"10.2169/naika.104.1918_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"},{"@type":"CROSSREF","@value":"10.2169/naika.108.547_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"},{"@type":"CROSSREF","@value":"10.1007/s12185-020-03054-x_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"},{"@type":"CROSSREF","@value":"10.1007/s12185-015-1746-8_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.55.6214_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"},{"@type":"CROSSREF","@value":"10.3109/10428194.2014.969260_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"},{"@type":"CROSSREF","@value":"10.2169/naika.108.1448_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"},{"@type":"CROSSREF","@value":"10.1182/bloodadvances.2020003303_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"},{"@type":"CROSSREF","@value":"10.1038/s41408-023-00869-9_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"},{"@type":"CROSSREF","@value":"10.7889/hct.1.15_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"},{"@type":"CROSSREF","@value":"10.1254/fpj.146.54_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"},{"@type":"CROSSREF","@value":"10.1620/tjem.228.295_references_DOI_PNRrRojS8msLSxhLrrJNuI0RqKZ"}]}